Fate Therapeutics Inc
NASDAQ: FATE
$2.68
-$0.08 (-2.9%)
Closing Price on November 5, 2024
FATE Articles
In a recent report from Wedbush Securities, the boutique brokerage firm recaps the COVID-19 impact on its coverage universe. Here, 24/7 Wall St. has picked out some of Wedbush’s top picks within...
Published:
Wednesday's top analyst upgrades, downgrades and initiations included Altria, Beyond Meat, Chevron, Chipotle Mexican Grill, Epizyme, FedEx, Home Depot, Mattel, Morgan Stanley, Oracle, Qualcomm and...
Published:
Last Updated:
The American Society of Hematology (ASH) hosted its 61st annual meeting and one of the biggest biotech events earlier this week in Orlando, Florida.
Published:
Fate Therapeutics shares jumped on Monday after the firm announced new preclinical data for its off-the-shelf, multi-antigen targeting natural killer cell product candidate derived from a clonal...
Published:
Tuesday's top analyst upgrades, downgrades and initiations included Analog Devices, Blackstone, Bloom Energy, Cleveland-Cliffs, Ford, Micron Technology, PG&E, Snap and VMWare.
Published:
Last Updated: